JPWO2005097152A1 - Turmeric extract-containing composition with improved caking properties - Google Patents

Turmeric extract-containing composition with improved caking properties Download PDF

Info

Publication number
JPWO2005097152A1
JPWO2005097152A1 JP2006511991A JP2006511991A JPWO2005097152A1 JP WO2005097152 A1 JPWO2005097152 A1 JP WO2005097152A1 JP 2006511991 A JP2006511991 A JP 2006511991A JP 2006511991 A JP2006511991 A JP 2006511991A JP WO2005097152 A1 JPWO2005097152 A1 JP WO2005097152A1
Authority
JP
Japan
Prior art keywords
turmeric extract
containing composition
turmeric
weight
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006511991A
Other languages
Japanese (ja)
Inventor
俊則 池原
俊則 池原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaneka Corp
Original Assignee
Kaneka Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaneka Corp filed Critical Kaneka Corp
Publication of JPWO2005097152A1 publication Critical patent/JPWO2005097152A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9066Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)

Abstract

極めて有用な生理作用を有するウコン抽出物の利用に関し、ウコン抽出物が有する高粘度の油状で粘結性を呈すなどの好ましくない性状を改善することで、流動性の悪さや容器等への付着の問題を解決し、そのままでは極めて扱いにくくウコン抽出物を高濃度に含有する組成物を提供する。ウコン抽出物を40重量%を超えて含有し、且つ、油脂及び/又はHLB値が8.5以下の親油性乳化剤をからなることを特徴とするウコン抽出物含有組成物を用いて、ウコンの有用成分を高濃度でソフトカプセル等へ封入する。Regarding the use of turmeric extract with extremely useful physiological action, by improving undesirable properties such as causticity due to the high viscosity oil of turmeric extract, poor fluidity and adhesion to containers, etc. Thus, the present invention provides a composition containing a high concentration of turmeric extract which is extremely difficult to handle as it is. Using a turmeric extract-containing composition characterized by comprising a turmeric extract in excess of 40% by weight and comprising a fat and oil and / or a lipophilic emulsifier having an HLB value of 8.5 or less, Useful components are encapsulated in soft capsules at high concentrations.

Description

本発明は、マルチプル・リスク・ファクター症候群を予防又は改善する効果を有するウコン抽出物の利用を容易にした、粘結性が改善されたウコン抽出物含有組成物に関する。   The present invention relates to a turmeric extract-containing composition with improved caking properties that facilitates the use of a turmeric extract having an effect of preventing or improving multiple risk factor syndrome.

ショウガ科ウコン属に分類されるウコン(春ウコン:Curcuma aromatica、秋ウコン:Curcuma longa)は、一般的にはカレースパイスの一つであるターメリックとして知られており、広く食用として利用されている。一方、中国の漢方、インドのアーユルヴェーダ、インドネシアのジャムー等の伝統療法においては、止血作用、健胃作用、抗菌作用、抗炎症作用があることが古くから知られており、薬用としても利用されている。また、ウコン及び主要成分クルクミンの効能が着目され、抗酸化作用、胆汁分泌促進作用(利胆作用)、内臓(肝臓、膵臓)機能増強作用、発癌抑制作用、脂質代謝改善作用、美白作用等様々な生理作用が明らかにされてきている。更には、ウコン抽出物に、内臓脂肪型肥満、糖尿病、高脂血症、高血圧症等のマルチプル・リスク・ファクター症候群を予防又は改善する効果を有することが知られている(国際公開第02/47699号パンフレット)、ウコンは様々な機能を有する極めて有用な素材である。   Turmeric (Spring turmeric: Curcuma aromatica, fall turmeric: Curcuma longa), which is classified into the genus Turmeric genus, is generally known as turmeric, one of the curry spices, and is widely used for food. On the other hand, traditional therapies such as Chinese herbal medicine, Ayurveda in India, and Jamu in Indonesia have long been known to have hemostatic, stomachic, antibacterial and anti-inflammatory effects and are also used as medicinal products. ing. In addition, attention is paid to the effects of turmeric and the main component curcumin. Antioxidant action, bile secretion promoting action (biliary action), visceral (liver, pancreas) function enhancing action, carcinogenesis suppressing action, lipid metabolism improving action, whitening action, etc. Physiological effects have been clarified. Furthermore, it is known that the turmeric extract has an effect of preventing or ameliorating multiple risk factor syndromes such as visceral fat obesity, diabetes, hyperlipidemia, hypertension and the like (International Publication No. 02 / 47699 pamphlet), turmeric is a very useful material having various functions.

しかしながらウコン抽出物(ウコンオレオレジン)は、クルクミン及びクルクミン誘導体(クルクミノイド)の他にビサボラン型セスキテルペン等のテルペン類を含有している為、その性状は高粘度の油状で粘結性を呈し、流動性の悪さや容器等への付着の問題からそのままでは極めて扱いにくく、例えばソフトカプセル等へ封入することも極めて困難であった。しかも、水やトリグリセリドに溶けにくく、溶液にするにはアルコールやケトン系の有機溶媒を用いなければならない等、ウコン抽出物の利用を困難にし用途が制限されてきた。尚、前記の国際公開第02/47699号パンフレットに於いて、ウコン抽出物を用いたソフトカプセルの記載(ウコン抽出物40重量部、ゴマ油55重量部、グリセリン脂肪酸エステル5重量部)があるが、ウコン抽出物の性状に関する記載はなく、配合されている乳化剤に関する詳細について具体的に言及もされておらず、実際にグリセリン脂肪酸エステルとしてエマルジーMS(理研ビタミン株式会社製、HLB=4.3)を用いて粘結性を評価した所、ソフトカプセルを何とか実験室レベルでは作れたが、工業的にはソフトカプセルを作るには実用的でない粘結性であった。従って、本発明に対して何ら示唆を与えるものではないことは明らかである。   However, the turmeric extract (turmeric oleoresin) contains terpenes such as bisaborane-type sesquiterpenes in addition to curcumin and curcumin derivatives (curcuminoids), so its properties are highly viscous oily and caking. Due to the poor fluidity and the problem of adhesion to containers and the like, it is extremely difficult to handle as it is, and for example, it is extremely difficult to enclose it in a soft capsule or the like. In addition, it is difficult to dissolve in water and triglycerides, and the use of the turmeric extract has been made difficult, such as the use of alcohol or ketone-based organic solvents to make a solution. In the above-mentioned pamphlet of International Publication No. 02/47699, there is a description of soft capsules using turmeric extract (turmeric extract 40 parts by weight, sesame oil 55 parts by weight, glycerin fatty acid ester 5 parts by weight). There is no description regarding the properties of the extract, and there is no specific mention about the details of the emulsifier incorporated, and actually using Emulsy MS (manufactured by Riken Vitamin Co., Ltd., HLB = 4.3) as the glycerin fatty acid ester. As a result of the evaluation of caking properties, it was possible to make soft capsules at the laboratory level, but industrially, the caking properties were not practical for making soft capsules. Therefore, it is clear that no suggestion is given to the present invention.

この様なウコン抽出物を利用する際の問題点を解決する手段として、ウコン抽出物とツェインの混合物が提案されている(特開平9−111282)。この方法によれば、常温で非粘結性の固体を得ることが可能であるが、ウコン抽出物含量は50%程度が限界である。また、製造工程で含水エタノール等の有機溶剤を使用すること、及びその溶液を乾燥する工程が必要であることから、その製品は高価とならざるを得ない。   As a means for solving such problems when using the turmeric extract, a mixture of turmeric extract and zein has been proposed (Japanese Patent Laid-Open No. 9-111282). According to this method, it is possible to obtain a non-caking solid at room temperature, but the turmeric extract content is limited to about 50%. In addition, since an organic solvent such as water-containing ethanol is used in the manufacturing process and a process for drying the solution is required, the product must be expensive.

また、ウコン粉末から食用油脂やジグリセリドによる抽出も提案されている(特開2001−86931、特開2003−137799)。この方法によれば、ウコンの有効成分を含むオイルを得ることが可能であるが、その濃度は本発明のように高濃度ではなく、クルクミンの濃度で僅か1%程度に過ぎず、十分な生理作用を得る為には該オイルを大量に摂取することになり、実用的なものではなかった。
国際公開第02/47699号 特開平9−111282号 特開2001−86931号 特開2003−137799号
In addition, extraction from turmeric powder with edible fats and oils or diglycerides has also been proposed (JP 2001-86931 A, JP 2003-137799 A). According to this method, it is possible to obtain an oil containing an active ingredient of turmeric, but the concentration is not as high as in the present invention, and is only about 1% in terms of curcumin concentration. In order to obtain the action, the oil was consumed in a large amount, which was not practical.
International Publication No. 02/47699 JP-A-9-111282 JP 2001-86931 A JP 2003-137799 A

本発明の目的は、極めて有用な生理作用を有するウコン抽出物の利用に関し、上述の好ましくない性状を改善することで、流動性の悪さや容器等への付着の問題を解決し、そのままでは極めて扱いにくいウコン抽出物を高濃度に含有する組成物を提供することにある。   The object of the present invention relates to the use of a turmeric extract having a very useful physiological action, and solves the problems of poor fluidity and adhesion to containers, etc. by improving the above-mentioned undesirable properties. The object is to provide a composition containing a difficult-to-handle turmeric extract in a high concentration.

上記実情に鑑み、本発明者らは鋭意研究の結果、ウコン抽出物と食用油脂及び/又は特定の乳化剤を混合することにより粘結性が著しく改善され、ウコン抽出物を高濃度に含有しても良好な流動性を有するスラリーが得られることを見出し、本発明を完成するに至った。   In view of the above situation, as a result of intensive studies, the present inventors have significantly improved caking properties by mixing turmeric extract with edible oils and fats and / or specific emulsifiers, and contain turmeric extract at a high concentration. The present inventors have found that a slurry having good fluidity can be obtained and completed the present invention.

即ち、本発明の第1は、ウコン抽出物を40重量%を超えて含有し、且つ、中鎖脂肪酸トリグリセリド及び/又は油脂及び/又はHLB値が8.5以下の親油性乳化剤からなることを特徴とするウコン抽出物含有組成物に関する。好ましい実施態様は、中鎖脂肪酸トリグリセリド及び/又はHLB値が8.5以下の親油性乳化剤からなることを特徴とする上記記載のウコン抽出物含有組成物に関する。より好ましくは、親油性乳化剤がグリセリン脂肪酸エステルであることを特徴とする上記記載のウコン抽出物含有組成物、更に好ましくは親油性乳化剤がポリグリセリン脂肪酸エステルであることを特徴とする上記記載のウコン抽出物含有組成物、特に好ましくはポリグリセリン脂肪酸エステルの構成脂肪酸が不飽和脂肪酸であることを特徴とする上記記載のウコン抽出物含有組成物、極めて好ましくは親油性乳化剤がジグリセリンモノオレイン酸エステルであることを特徴とする上記記載のウコン抽出物含有組成物、最も好ましくはマルチプル・リスク・ファクター症候群を予防又は改善する効果を有することを特徴とする上記記載のウコン抽出物含有組成物、に関する。   That is, the first of the present invention comprises a turmeric extract containing more than 40% by weight and comprising a medium-chain fatty acid triglyceride and / or fat and / or a lipophilic emulsifier having an HLB value of 8.5 or less. The present invention relates to a turmeric extract-containing composition. A preferred embodiment relates to the turmeric extract-containing composition as described above, comprising a medium-chain fatty acid triglyceride and / or a lipophilic emulsifier having an HLB value of 8.5 or less. More preferably, the turmeric extract-containing composition as described above, wherein the lipophilic emulsifier is a glycerin fatty acid ester, and more preferably, the turmeric as described above, wherein the lipophilic emulsifier is a polyglycerol fatty acid ester. Extract-containing composition, particularly preferably the constituent fatty acid of polyglycerol fatty acid ester is an unsaturated fatty acid, the turmeric extract-containing composition as described above, very preferably the lipophilic emulsifier is diglycerol monooleate The turmeric extract-containing composition as described above, characterized in that, most preferably, the turmeric extract-containing composition as described above, which has an effect of preventing or improving multiple risk factor syndrome .

本発明の第2は、上記記載の組成物を封入してなるカプセルに関する。   The second of the present invention relates to a capsule encapsulating the above-described composition.

ウコン抽出物を高濃度に含有するにもかかわらず、粘度が高くなく、且つ容器などへの付着性が低い組成物を提供できる。従って、例えばウコンの有用成分を高濃度でソフトカプセル等へ封入することも容易になる。   In spite of containing the turmeric extract at a high concentration, it is possible to provide a composition having a low viscosity and low adhesion to a container or the like. Therefore, for example, it becomes easy to enclose a useful component of turmeric in a soft capsule or the like at a high concentration.

本発明のウコン抽出物含有組成物は、極めて有用な生理活性を有するものの、高粘度で粘結性を有し流動性が悪く容器への付着が多いという問題を有する高濃度のウコン抽出物に、中鎖脂肪酸トリグリセリド及び/又は油脂及び/又はHLB値が8.5以下の親油性乳化剤を混合することにより、流動性、付着性および均一性に優れるという利点を有する。また本発明のウコン抽出物含有組成物は高濃度のウコン抽出物を含有するのでマルチプル・リスク・ファクター症候群の予防又は改善する効果を有するという利点を有する。更に本発明のウコン抽出物含有組成物は流動性、付着性および均一性に優れるので、高濃度のウコン抽出物を封入したソフトカプセルを容易に製造できるという利点を有する。 The turmeric extract-containing composition of the present invention is a highly concentrated turmeric extract that has extremely useful physiological activity, but has a problem of high viscosity, caking property, poor fluidity, and high adhesion to containers. By mixing medium chain fatty acid triglycerides and / or fats and oils and / or lipophilic emulsifiers having an HLB value of 8.5 or less, there is an advantage of excellent fluidity, adhesion and uniformity. Moreover, since the turmeric extract containing composition of this invention contains a high concentration turmeric extract, it has the advantage that it has the effect of preventing or improving a multiple risk factor syndrome. Furthermore, since the composition containing turmeric extract of the present invention is excellent in fluidity, adhesion and uniformity, it has an advantage that a soft capsule encapsulating a high concentration of turmeric extract can be easily produced.

以下に、本発明を詳しく説明する。本発明のウコン抽出物含有組成物は、ウコン抽出物に対し、流動性を改善する油脂成分、及び/又は、粘結牲を改善する親油性乳化剤を配合してなるものである。   The present invention is described in detail below. The turmeric extract containing composition of this invention mix | blends the fats and oils component which improves fluidity, and / or the lipophilic emulsifier which improves caking property with respect to a turmeric extract.

本発明のウコン抽出物の製法は特に限定されず、従来からの公知の方法、例えばウコンの根茎部を温エタノールで抽出する方法により得ることが可能である。また、市販のウコンオレオレジンをそのまま用いることも可能である。   The production method of the turmeric extract of the present invention is not particularly limited, and can be obtained by a conventionally known method, for example, a method of extracting the rhizome part of turmeric with warm ethanol. Commercially available turmeric oleoresin can also be used as it is.

更に、本発明に用いるウコン抽出物は、クルクミン、クルクミン誘導体(例えば、デメトキシクルクミン、ビスデメトキシクルクミン、ジヒドロクルクミン、テトラヒドロクルクミン、ヘキサヒドロクルクミン、ジヒドロキシテトラクルクミン等)及び、ビサボラン型セスキテルペンとして、例えば、β−ビサボレン、α−クルクメン、ジンギベレン、β−セスキフェランドレン、ar−ターメロン、α−ターメロン、β−ターメロン等を含有する。   Furthermore, the turmeric extract used in the present invention includes curcumin, curcumin derivatives (for example, demethoxycurcumin, bisdemethoxycurcumin, dihydrocurcumin, tetrahydrocurcumin, hexahydrocurcumin, dihydroxytetracurcumin, etc.) and bisaborane-type sesquiterpenes, For example, it contains β-bisaborane, α-curcumene, gingiberene, β-sesquiferlandene, ar-turmerone, α-turmerone, β-turmerone and the like.

本発明に用いられる中鎖脂肪酸トリグリセリド(以下MCTとも記載する)は、構成脂肪酸残基として炭素数6〜10の脂肪酸残基を有するトリグリセリドである。   The medium chain fatty acid triglyceride (hereinafter also referred to as MCT) used in the present invention is a triglyceride having a fatty acid residue having 6 to 10 carbon atoms as a constituent fatty acid residue.

本発明に用いられる油脂は、中鎖脂肪酸トリグリセリド以外の食用油脂のことであり、それ以外に特に限定は無い。例えば、コーン油、ナタネ油、ハイエルシンナタネ油、大豆油、オリーブ油、紅花油、綿実油、ヒマワリ油、米糠油、パーム油、パーム核油等の植物油、魚油、牛脂、豚脂、乳脂、卵黄油等の動物油、又はこれらを原料として分別、水添、エステル交換等を行った油脂、或いはこれらの混合油が使用できる。また、食品以外の用途であれば上記動植物油脂以外の油脂を選択することも可能である。   The fats and oils used in the present invention are edible fats and oils other than medium-chain fatty acid triglycerides, and there is no particular limitation other than that. For example, corn oil, rapeseed oil, Haieru rapeseed oil, soybean oil, olive oil, safflower oil, cottonseed oil, sunflower oil, rice bran oil, palm oil, palm kernel oil and other vegetable oils, fish oil, beef tallow, pork fat, milk fat, egg yolk oil Animal oils such as these, oils and fats that have been subjected to fractionation, hydrogenation, transesterification, etc. using these as raw materials, or mixed oils thereof can be used. Moreover, if it is uses other than foodstuff, it is also possible to select fats and oils other than the said animal and vegetable fats and oils.

本発明に用いられる親油性乳化剤としてはウコン抽出物又はウコン抽出物及び油脂と均一に混合できれば特に限定されないが、HLB値は8.5以下が好ましく、より好ましくは3〜8.5、更に好ましくは5〜8.5である。これは、ウコンの抽出を行う際に使用する溶剤の親油性に近い方が好ましいためである。但し、ここで言う親油性とは油脂に溶解可能と言うことであり、MCTや一般の食用油脂に溶解可能なものを親油性乳化剤とする。HLB値が8.5を超えると、ウコン抽出物及び油脂と乳化剤とが分離する場合がある。   The lipophilic emulsifier used in the present invention is not particularly limited as long as it can be uniformly mixed with the turmeric extract or the turmeric extract and the oil and fat, but the HLB value is preferably 8.5 or less, more preferably 3 to 8.5, and still more preferably. Is 5 to 8.5. This is because it is preferable that the solvent used in the extraction of turmeric is close to the lipophilicity. However, the term “lipophilic” as used herein means that it is soluble in fats and oils, and those that are soluble in MCT and general edible fats and oils are used as lipophilic emulsifiers. When the HLB value exceeds 8.5, the turmeric extract, the oil and fat, and the emulsifier may be separated.

尚、HLB値とは、一般に乳化剤の親水性と親油性の程度を表す尺度であり、その値が小さいほど親油性が強い。HLB値の求め方は特に限定するものではないが、例えば、下式により求めることができる(化学辞典、東京化学同人、第1版、1994年10月1日発行参照)。   The HLB value is a scale generally indicating the degree of hydrophilicity and lipophilicity of an emulsifier, and the smaller the value, the stronger the lipophilicity. The method for obtaining the HLB value is not particularly limited. For example, the HLB value can be obtained by the following formula (see Chemical Dictionary, Tokyo Chemical Doujin, 1st edition, issued on October 1, 1994).

HLB=20×(1−S/A)
S:エステルのケン化価、A:脂肪酸の酸価
この様な乳化剤としては、例えばモノグリセリン脂肪酸エステル、モノグリセリン脂肪酸有機酸エステル、ポリグリセリン脂肪酸エステル、ポリグリセリン縮合リシノール酸エステル等のグリセリン脂肪酸エステル類、ソルビタン脂肪酸エステル類、ポリソルベート類、ショ糖脂肪酸エステル類、プロピレングリコール脂肪酸エステル類、レシチン類等が挙げられ、それぞれ少なくとも1種を混合して使用することができる。中でも、効果的に粘結性を改善できることからグリセリン脂肪酸エステル類が好ましく、ポリグリセリン脂肪酸エステル、ポリグリセリン縮合リシノール酸エステルがより好ましい。本発明で言う粘結性とは、流動性、容器への付着性、ウコン抽出物含有組成物各成分の均一性のバランスを意味し、前記3種の性質が良好な程、粘結性も良いことを意味する。
HLB = 20 × (1-S / A)
S: Saponification value of ester, A: Acid value of fatty acid Examples of such an emulsifier include glycerin fatty acid esters such as monoglycerin fatty acid ester, monoglycerin fatty acid organic acid ester, polyglycerin fatty acid ester, and polyglycerin condensed ricinoleic acid ester. , Sorbitan fatty acid esters, polysorbates, sucrose fatty acid esters, propylene glycol fatty acid esters, lecithins and the like, and at least one of them can be used in combination. Among these, glycerin fatty acid esters are preferable because the caking property can be effectively improved, and polyglycerin fatty acid esters and polyglycerin condensed ricinoleic acid esters are more preferable. The caking property referred to in the present invention means a balance between fluidity, adhesion to a container, and uniformity of each component of the turmeric extract-containing composition. Means good.

前記ポリグリセリン脂肪酸エステル及びポリグリセリン縮合リシノール酸エステルとしては、ポリグリセリンの平均重合度が2〜10が例示される。更に、ポリグリセリン脂肪酸エステルは構成脂肪酸の炭素数が6〜22の脂肪酸であるものが例示され、中でも構成脂肪酸が不飽和脂肪酸であることが好ましく、例えば、ジグリセリンモノオレイン酸エステル、テトラグリセリンペンタオレイン酸エステル、ヘキサグリセリンペンタオレイン酸エステル、ペンタグリセリントリオレイン酸エステル、デカグリセリンペンタオレイン酸エステル、デカグリセリンデカオレイン酸エステル、デカグリセリンデカエルカ酸エステル等が好適であり、より好ましくは、ジグリセリンモノオレイン酸エステルである。   Examples of the polyglycerin fatty acid ester and the polyglycerin condensed ricinoleic acid ester include those having an average degree of polymerization of polyglycerin of 2 to 10. Furthermore, the polyglycerin fatty acid ester is exemplified by fatty acids having 6 to 22 carbon atoms in the constituent fatty acid. Among them, the constituent fatty acid is preferably an unsaturated fatty acid, for example, diglycerin monooleate, tetraglycerin penta Preferred are oleic acid ester, hexaglycerin pentaoleic acid ester, pentaglycerin trioleic acid ester, decaglycerin pentaoleic acid ester, decaglycerin dekaoleic acid ester, decaglycerin decaerucic acid ester, and more preferably diglycerin. Monooleate.

前記MCT、油脂、HLB値が8.5以下の親油性乳化剤は、ウコン抽出物と均一に混合できるのであれば、それらの内少なくとも1種を用いることができる。ウコン抽出物の含有量が増える程、MCT及び/又はHLB値が8.5以下の親油性乳化剤が好ましく、MCT及びHLB値が8.5以下の親油性乳化剤の混合物がより好ましい。MCTは、一般の油脂に比べて粘度が低く、且つ体脂肪抑制効果が知られており、一般の油脂と比べて均一且つ微細なスラリーとなるために流動性及び均一性の改善効果が大きく、HLB値が8.5以下の親油性乳化剤は、付着性の改善効果が大きい。   If the said MCT, fats and oils, and the lipophilic emulsifier whose HLB value is 8.5 or less can be mixed uniformly with a turmeric extract, at least 1 sort (s) of them can be used. As the content of the turmeric extract increases, a lipophilic emulsifier having an MCT and / or HLB value of 8.5 or less is preferable, and a mixture of a lipophilic emulsifier having an MCT and HLB value of 8.5 or less is more preferable. MCT has a low viscosity compared to general fats and oils and is known to have a body fat suppression effect. Compared with general fats and oils, MCT has a uniform and fine slurry, and thus has a large effect of improving fluidity and uniformity. A lipophilic emulsifier having an HLB value of 8.5 or less has a great effect of improving adhesion.

ここでウコン抽出物含有組成物中のウコン抽出物と中鎖脂肪酸トリグリセリド及び/又は油脂及び/又はHLB値が8.5以下の親油性乳化剤の含有量について詳述する。本発明の中鎖脂肪酸トリグリセリド及び/又は油脂及び/又は及び/又はHLB値が8.5以下の親油性乳化剤とは、MCT単独、油脂単独、HLB値が8.5以下の親油性乳化剤単独、MCTと油脂の併用、MCTとHLB値が8.5以下の親油性乳化剤との併用、油脂とHLB値が8.5以下の親油性乳化剤との併用、MCTと油脂とHLB値が8.5以下の親油性乳化剤との併用、である。これらの組み合わせは、ウコン抽出物の含有量によって適宜選択することができる。   Here, the content of the turmeric extract and the medium-chain fatty acid triglyceride and / or fat and oil and / or the lipophilic emulsifier having an HLB value of 8.5 or less in the turmeric extract-containing composition will be described in detail. The medium-chain fatty acid triglycerides and / or fats and / or fats and / or lipophilic emulsifiers having an HLB value of 8.5 or less are MCT alone, fats and oils alone, lipophilic emulsifiers having an HLB value of 8.5 or less, Combined use of MCT and oil, combined use of MCT and lipophilic emulsifier having an HLB value of 8.5 or less, combined use of fat and oil and lipophilic emulsifier having an HLB value of 8.5 or less, MCT, fat and oil and HLB value of 8.5 Use in combination with the following lipophilic emulsifiers. These combinations can be appropriately selected depending on the content of the turmeric extract.

即ち、ウコン抽出物含有組成物中のウコン抽出物含有量が40重量%以下の場合、MCT及び/又は油脂及び/又はHLB値が8.5以下の親油性乳化剤は60重量%以上である。この場合、MCT単独、油脂単独、親油性乳化剤単独、MCTと油脂の併用、MCTと親油性乳化剤との併用、油脂と親油性乳化剤との併用、MCTと油脂と親油性乳化剤との併用、何れの組み合わせでも良い。   That is, when the content of the turmeric extract in the turmeric extract-containing composition is 40% by weight or less, the MCT and / or fat and oil and / or the lipophilic emulsifier having an HLB value of 8.5 or less is 60% by weight or more. In this case, MCT alone, fat and oil alone, lipophilic emulsifier alone, combined use of MCT and fat and oil, combined use of MCT and lipophilic emulsifier, combined use of fat and oil and lipophilic emulsifier, combined use of MCT, fat and oil and lipophilic emulsifier, A combination of

同様に、ウコン抽出物含有量が40重量%を超えて50重量%未満の場合は、MCT単独、親油性乳化剤単独、MCTと油脂の併用、MCTと親油性乳化剤との併用、油脂と親油性乳化剤との併用、MCTと油脂と親油性乳化剤との併用、何れの組み合わせでも良く、その総量は50重量%を超えて、且つ60重量%未満の範囲である。油脂単独では粘結性の改善効果が実用的でない場合があるため、MCTとの併用もしくは、親油性乳化剤との併用が好ましく、油脂と親油性乳化剤の重量比率は99.9/0.1〜0.1/99.9が好ましく、より好ましくは90/10〜0.1/99.9である。流動性を優先する場合は油脂の比率を高く、付着牲の改善を優先する場合は親油性乳化剤の重量比率をそれぞれ高く設定することが好ましい。   Similarly, when the content of turmeric extract is more than 40% by weight and less than 50% by weight, MCT alone, lipophilic emulsifier alone, combined use of MCT and fat, combined use of MCT and lipophilic emulsifier, fat and fat and lipophilic Any combination of emulsifiers, MCT, fats and oils and lipophilic emulsifiers may be used, and the total amount is in the range of more than 50% by weight and less than 60% by weight. Since the effect of improving the caking property may not be practical when the oil or fat is used alone, the combined use with MCT or the combined use of the lipophilic emulsifier is preferable, and the weight ratio of the oil and fat to the lipophilic emulsifier is 99.9 / 0.1 0.1 / 99.9 is preferable, and 90/10 to 0.1 / 99.9 is more preferable. When giving priority to fluidity, it is preferable to set the ratio of fats and oils high, and when giving priority to improving adhesion, the weight ratio of the lipophilic emulsifier is preferably set high.

また、ウコン抽出物含有量が50重量%以上、且つ60重量%未満の場合は、MCT単独、親油性乳化剤単独、MCTと油脂の併用、MCTと親油性乳化剤との併用、油脂と親油性乳化剤との併用、MCTと油脂と親油性乳化剤との併用、何れの組み合わせでも良く、その総量は40重量%を超えて、且つ50重量%以下の範囲である。油脂単独では粘結性の改善効果が十分でない場合があるため、油脂とMCTとの併用もしくは、油脂と親油性乳化剤との併用が好ましく、流動性と付着性両方の大きな改善を達成しようとすると、MCTと親油性乳化剤との併用がより好ましい。油脂と親油性乳化剤との併用の場合の油脂と親油性乳化剤の重量比率は90/10〜0.1/99.9が好ましく、より好ましくは75/25〜0.1/99.9であり、ウコン抽出物含有量が40重量%を超えて50重量%未満の場合に比べて乳化剤比率が高い範囲設定となる。油脂とMCTとの併用の場合の油脂とMCTの重量比率は、90/10〜0.1/99.9が好ましく、より好ましくは70/30〜0.1/99.9、更に好ましくは50/50〜0.1/99.9であり、ウコン抽出物含有量が40重量%を超えて50重量%未満の場合に比べてMCT比率が高い範囲設定となる。流動性を優先する場合は油脂の比率を高く、付着牲の改善を優先する場合は親油性乳化剤の重量比率をそれぞれ高く設定することが好ましい。また、MCTと親油性乳化剤との併用の場合のMCTと親油性乳化剤の重量比率は90/10〜10/90が好ましい。この範囲であれば、流動性と付着性が共に大きく改善される。   When the content of turmeric extract is 50 wt% or more and less than 60 wt%, MCT alone, lipophilic emulsifier alone, combined use of MCT and fat, combined use of MCT and lipophilic emulsifier, fat and lipophilic emulsifier Or a combination of MCT, fats and oils, and a lipophilic emulsifier, any combination may be used, and the total amount is in the range of more than 40% by weight and 50% by weight or less. Since fats and oils alone may not have sufficient caking improvement effect, the combined use of fats and fats or MCT or the combination of fats and fats and lipophilic emulsifiers is preferred, and when trying to achieve great improvements in both fluidity and adhesion The combined use of MCT and a lipophilic emulsifier is more preferred. In the case of the combined use of fats and oils and lipophilic emulsifiers, the weight ratio of fats and fats and lipophilic emulsifiers is preferably 90/10 to 0.1 / 99.9, more preferably 75/25 to 0.1 / 99.9. The content ratio of the emulsifier is higher than when the content of the turmeric extract is more than 40% by weight and less than 50% by weight. 90/10 to 0.1 / 99.9 is preferable, and the weight ratio of oil and MCT in the case of the combined use of oil and fat and MCT is more preferably 70/30 to 0.1 / 99.9, still more preferably 50. / 50 to 0.1 / 99.9, and the MCT ratio is set to a higher range than when the content of the turmeric extract is more than 40% by weight and less than 50% by weight. When giving priority to fluidity, it is preferable to set the ratio of fats and oils high, and when giving priority to improving adhesion, the weight ratio of the lipophilic emulsifier is preferably set high. Further, the weight ratio of MCT and lipophilic emulsifier in the combined use of MCT and lipophilic emulsifier is preferably 90/10 to 10/90. Within this range, both fluidity and adhesion are greatly improved.

更には、ウコン抽出物含有量が60重量%以上の場合は、MCTと親油性乳化剤との併用、油脂と親油性乳化剤との併用、MCTと油脂と親油性乳化剤との併用が好ましく、中でもMCTと親油性乳化剤の併用がより好ましく、その総量は40重量%以下である。MCTと親油性乳化剤を併用する場合、MCTと親油性乳化剤の重量比率は特に限定されないが、好ましくは0.1/99.9〜99.9/0.1、より好ましくは10/90〜90/10、更に好ましくは、25/75〜75/25、最も好ましくは40/60〜60/40の範囲であり、流動性を優先する場合は油脂の比率を高く、付着牲の改善を優先する場合は親油性乳化剤の重量比率をそれぞれ高く設定することが好ましい。   Furthermore, when the content of turmeric extract is 60% by weight or more, the combined use of MCT and lipophilic emulsifier, the combined use of fat and oil and lipophilic emulsifier, the combined use of MCT, fat and oil and lipophilic emulsifier is preferable. And a lipophilic emulsifier are more preferred, and the total amount is 40% by weight or less. When MCT and a lipophilic emulsifier are used in combination, the weight ratio of MCT to the lipophilic emulsifier is not particularly limited, but is preferably 0.1 / 99.9 to 99.9 / 0.1, more preferably 10/90 to 90. / 10, more preferably 25/75 to 75/25, most preferably in the range of 40/60 to 60/40. When fluidity is prioritized, the ratio of fats and oils is increased, and improvement of adhesion is prioritized. In this case, it is preferable to set the weight ratio of the lipophilic emulsifier high.

ウコン抽出物含有組成物の調整は、必要に応じて加温条件下で行うことが好ましく、20〜60℃程度で調整することがより好ましい。具体的には、調整に際しては、所定量のウコン抽出物と所定量の油脂及び/又は親油性乳化剤を、所定の温度での加温条件下で撹拌により均一に混合すればよく、例えばパドルミキサー、ホモミキサー、ホモジナイザー、高圧ホモジナイザー、コロイドミル、ビーズミル等を用いることができる。   Adjustment of the turmeric extract-containing composition is preferably performed under heating conditions as necessary, and more preferably adjusted at about 20 to 60 ° C. Specifically, for adjustment, a predetermined amount of turmeric extract and a predetermined amount of oil and / or lipophilic emulsifier may be uniformly mixed by stirring under a heating condition at a predetermined temperature. For example, a paddle mixer , Homomixers, homogenizers, high-pressure homogenizers, colloid mills, bead mills, and the like can be used.

上述の方法により調整されたウコン抽出物含有組成物は、そのまま食品へ添加することも可能であるが、より効果的に摂取するためにはカプセル形態とするのが好ましく、例えば、ソフトカプセル、ハードカプセル、シームレスカプセル等を用いることができる。更にウコン抽出物組成物に対して、目的に応じて、ビタミンA,C,D,E等の各種ビタミン類、ミツロウ等の製剤用基剤等を更に添加してもよい。また、マルチプル・リスク・ファクター症候群を予防又は改善する効果を有する甘草疎水性抽出物、クローブ抽出物、シナモン抽出物等、あるいは一般に食品として用いられる素材、及び抗酸化剤等の食品添加物を添加してもよい。   The turmeric extract-containing composition prepared by the above-described method can be added to food as it is, but it is preferably in a capsule form in order to take it more effectively, for example, soft capsule, hard capsule, Seamless capsules can be used. In addition, various vitamins such as vitamins A, C, D, and E, and pharmaceutical preparations such as beeswax may be further added to the turmeric extract composition according to the purpose. In addition, licorice hydrophobic extract, clove extract, cinnamon extract, etc. that have the effect of preventing or improving multiple risk factor syndrome, or materials commonly used as food, and food additives such as antioxidants are added May be.

以下、実施例を挙げて本発明を更に具体的に説明するが、本発明はこれらの実施例に限定されるものではない。   EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated further more concretely, this invention is not limited to these Examples.

<流動性評価法>
50ccガラスビーカーにウコン抽出物含有組成物を20g入れ、25℃においてビーカーを下方45度に傾けた時の状態を観察した。その評価基準については以下の通りである。
◎:速やかに流れ出る、○:ゆっくりと流れ出る、△:40℃に加温するとゆっくりと流れ出る、×:40℃に加温してもほとんど流れ出ない、※:撹拌しても乳化剤が均一にならず、分離した状態で評価できない。
<Fluidity evaluation method>
20 g of the turmeric extract-containing composition was put into a 50 cc glass beaker, and the state when the beaker was tilted downward 45 degrees at 25 ° C. was observed. The evaluation criteria are as follows.
◎: Flows out quickly, ○: Flows out slowly, △: Flows out slowly when heated to 40 ° C, X: Almost does not flow even when heated to 40 ° C, *: Emulsifier does not become uniform even when stirred Cannot be evaluated in a separated state.

<付着性評価法>
50ccガラスビーカーにウコン抽出物含有組成物を20g入れ、25℃においてビーカーを下方45度に傾けた後、ビーカーを元に戻して30分静置後のビーカー内壁の状態を観察した。その評価基準については以下の通りである。◎:内壁への付着無し、○:僅かに内壁への付着有り、△:内壁へ粒状の付着有り、×:べっとりと内壁へ付着、※:撹拌しても乳化剤が均一にならず、分離した状態で評価できない。
<Adhesion evaluation method>
20 g of the turmeric extract-containing composition was put into a 50 cc glass beaker, and the beaker was tilted downward 45 degrees at 25 ° C., then the beaker was returned to its original state and the state of the inner wall of the beaker after standing for 30 minutes was observed. The evaluation criteria are as follows. ◎: No adhesion to the inner wall, ○: Slight adhesion to the inner wall, △: Grainy adhesion to the inner wall, ×: Sticky to the inner wall, *: Even after stirring, the emulsifier did not become uniform and separated Cannot be evaluated by condition.

<均一性評価法>
ウコン抽出物含有組成物の外観及び、内相を観察した。その評価基準については以下の通りである。◎:均一で微細なスラリー状態、○:均一であるが、粒状感のあるスラリー状態、△:撹拌すると均一になるが、静置すると短時間で固液分離した状態、×:撹拌しても乳化剤が均一にならず、分離した状態。
<Uniformity evaluation method>
The appearance and internal phase of the turmeric extract-containing composition were observed. The evaluation criteria are as follows. A: Uniform and fine slurry state, ○: Uniform but granular slurry state, Δ: Uniform when stirred, but solid and liquid separated in a short time after standing, X: Even when stirred The emulsifier is not uniform and separated.

(実施例1)
ウコンオレオレジン(丸善製薬株式会社製:クルクミノイド31%、テルペン類39%含有)50重量%、MCT(理研ビタミン株式会社製、商品名:アクターM2)25重量%、ジグリセリンモノオレイン酸エステル(理研ビタミン株式会社製、商品名:ポエムDO−100V、HLB値=8.0)25重量%を用い、40℃加温条件下でパドルミキサーにより混合した。得られたウコン抽出物含有組成物は、流動性、付着性及び均一性が大きく改善され、即ち粘結性が大きく改善された非常に良好な性状を示した(表1)。
(Example 1)
Turmeric oleoresin (manufactured by Maruzen Pharmaceutical Co., Ltd .: 31% curcuminoid and 39% terpene) 50% by weight, MCT (manufactured by Riken Vitamin Co., Ltd., trade name: Actor M2) 25% by weight, diglycerin monooleate (RIKEN) Vitamin Co., Ltd., trade name: Poem DO-100V, HLB value = 8.0) 25% by weight was mixed with a paddle mixer under 40 ° C. heating conditions. The obtained turmeric extract-containing composition showed very good properties with greatly improved flowability, adhesion and uniformity, ie, greatly improved caking properties (Table 1).

(実施例2)
ウコンオレオレジン(丸善製薬株式会社製)50重量%、MCT(理研ビタミン株式会社製、商品名:アクターM2)37.5重量%、ジグリセリンモノオレイン酸エステル(理研ビタミン株式会社製、商品名:ポエムDO−100V,HLB値=8.0)12.5重量%を用い、40℃加温条件下でパドルミキサーにより混合した。得られたウコン抽出物含有組成物は、流動性、付着性及び均一性が大きく改善され、即ち粘結性が大きく改善された非常に良好な性状を示した(表1)。
(Example 2)
Turmeric oleoresin (manufactured by Maruzen Pharmaceutical Co., Ltd.) 50% by weight, MCT (manufactured by Riken Vitamin Co., Ltd., trade name: Actor M2) 37.5% by weight, diglycerin monooleate (manufactured by Riken Vitamin Co., Ltd., trade name: (Poem DO-100V, HLB value = 8.0) 12.5% by weight was mixed by a paddle mixer under heating at 40 ° C. The obtained turmeric extract-containing composition showed very good properties with greatly improved flowability, adhesion and uniformity, ie, greatly improved caking properties (Table 1).

(実施例3)
ウコンオレオレジン(丸善製薬株式会社製)50重量%、MCT(理研ビタミン株式会社製、商品名:アクターM2)12.5重量%、ジグリセリンモノオレイン酸エステル(理研ビタミン株式会社製、商品名:ポエムDO−100V,HLB値=8.0)37.5重量%を用い、40℃加温条件下でパドルミキサーにより混合した。得られたウコン抽出物含有組成物は、流動性、付着性及び均一性が大きく改善され、即ち粘結性が大きく改善された非常に良好な性状を示した(表1)。
(Example 3)
Turmeric oleoresin (manufactured by Maruzen Pharmaceutical Co., Ltd.) 50% by weight, MCT (manufactured by Riken Vitamin Co., Ltd., trade name: Actor M2) 12.5% by weight, diglycerin monooleate (manufactured by Riken Vitamin Co., Ltd., trade name: (Poem DO-100V, HLB value = 8.0) 37.5% by weight was mixed with a paddle mixer under heating at 40 ° C. The obtained turmeric extract-containing composition showed very good properties with greatly improved flowability, adhesion and uniformity, ie, greatly improved caking properties (Table 1).

(実施例4)
ウコンオレオレジン(丸善製薬株式会社製)80重量%、MCT(理研ビタミン株式会社製、商品名:アクターM2)10重量%、ジグリセリンモノオレイン酸エステル(理研ビタミン株式会社製、商品名:ポエムDO−100V,HLB値=8.0)10重量%を用い、40℃加温条件下でパドルミキサーにより混合した。得られたウコン抽出物含有組成物は、流動性及び付着性が改善され、且つ均一性が大きく改善され、即ち粘結性が改善された良好な性状を示した(表1)。
Example 4
Turmeric oleoresin (manufactured by Maruzen Pharmaceutical Co., Ltd.) 80% by weight, MCT (manufactured by Riken Vitamin Co., Ltd., trade name: Actor M2) 10% by weight, diglycerin monooleate (manufactured by Riken Vitamin Co., Ltd., trade name: Poem DO 10% by weight of −100 V, HLB value = 8.0), and mixed by a paddle mixer under heating at 40 ° C. The obtained turmeric extract-containing composition showed good properties with improved flowability and adhesion, and greatly improved uniformity, ie, improved caking properties (Table 1).

(実施例5)
ウコンオレオレジン(丸善製薬株式会社製)50重量%、MCT(理研ビタミン株式会社製、商品名:アクターM2)5重量%、ペンタグリセリントリオレイン酸エステル(太陽化学株式会社製、商品名:サンファットA−173E,HLB値=7.0)45重量%を用い、40℃加温条件下でパドルミキサーにより混合した。得られたウコン抽出物含有組成物は、流動性が改善され、且つ付着性及び均一性が大きく改善され、粘結性が改善された良好な性状を示した(表1)。
(Example 5)
Turmeric oleoresin (manufactured by Maruzen Pharmaceutical Co., Ltd.) 50% by weight, MCT (manufactured by Riken Vitamin Co., Ltd., trade name: Actor M2), 5% by weight, pentaglycerin trioleate (manufactured by Taiyo Kagaku Co., Ltd., trade name: Sun Fat) A-173E, HLB value = 7.0) 45% by weight, and mixed by a paddle mixer under heating at 40 ° C. The resulting turmeric extract-containing composition showed good properties with improved flowability, greatly improved adhesion and uniformity, and improved caking properties (Table 1).

(実施例6)
ウコンオレオレジン(丸善製薬株式会社製)50重量%、MCT(理研ビタミン株式会社製、商品名:アクターM2)45重量%、ヘキサグリセリンペンタオレイン酸エステル(阪本薬品工業株式会社製、商品名:SYグリスターPO−5S,HLB値=4.9)5重量%を用い、40℃加温条件下でパドルミキサーにより混合した。得られたウコン抽出物含有組成物は、流動性及び均一性が大きく改善され、且つ付着性が改善され、粘結性が改善された良好な性状を示した(表1)。
(Example 6)
Turmeric oleoresin (manufactured by Maruzen Pharmaceutical Co., Ltd.) 50% by weight, MCT (manufactured by Riken Vitamin Co., Ltd., trade name: Actor M2) 45% by weight, hexaglycerin pentaoleate (manufactured by Sakamoto Pharmaceutical Co., Ltd., trade name: SY Glister PO-5S, HLB value = 4.9) 5% by weight was mixed with a paddle mixer under heating at 40 ° C. The obtained turmeric extract-containing composition showed good properties with greatly improved fluidity and uniformity, improved adhesion, and improved caking (Table 1).

(実施例7)
ウコンオレオレジン(丸善製薬株式会社製)45重量%、MCT(理研ビタミン株式会社製、商品名:アクターM2)55重量%を用い、40℃加温条件下でパドルミキサーにより混合した。得られたウコン抽出物含有組成物は、流動性が大きく改善され、且つ付着性及び均一性が改善され、粘結性が改善された良好な性状を示した(表1)。
(Example 7)
Turmeric oleoresin (manufactured by Maruzen Pharmaceutical Co., Ltd.) 45% by weight and MCT (manufactured by Riken Vitamin Co., Ltd., trade name: Actor M2) 55% by weight were mixed with a paddle mixer under 40 ° C. heating conditions. The obtained turmeric extract-containing composition showed good properties with greatly improved fluidity, improved adhesion and uniformity, and improved caking properties (Table 1).

(実施例8)
ウコンオレオレジン(丸善製薬株式会社製)45重量%、ジグリセリンモノオレイン酸エステル(理研ビタミン株式会社製、商品名:ポエムDO−100V,HLB値=8.0)55重量%を用い、40℃加温条件下でパドルミキサーにより混合した。得られたウコン抽出物含有組成物は、流動性及び均一性が改善され、且つ付着性が大きく改善され、粘結性が改善された良好な性状を示した(表1)。
(Example 8)
Using 40% by weight of turmeric oleoresin (manufactured by Maruzen Pharmaceutical Co., Ltd.) 45% by weight and 55% by weight of diglycerin monooleate (manufactured by Riken Vitamin Co., Ltd., trade name: Poem DO-100V, HLB value = 8.0) It mixed with the paddle mixer under the heating condition. The obtained turmeric extract-containing composition showed good properties with improved fluidity and uniformity, greatly improved adhesion, and improved caking (Table 1).

(実施例9)
実施例1のウコン抽出物含有組成物300mg、ミツロウ30mgを均一に混合した後、ロータリー式ソフトカプセル製造装置を用いてゼラチン皮膜に圧入し、内容量330mgのソフトカプセル剤を得た。調合タンク内およびソフトカプセル製造装置内への付着による内容物の残存量はごく僅かであり、工業的に何ら問題のないことが確認された。
Example 9
After uniformly mixing 300 mg of the turmeric extract-containing composition of Example 1 and 30 mg of beeswax, the mixture was press-fitted into the gelatin film using a rotary type soft capsule manufacturing apparatus to obtain a soft capsule having an internal volume of 330 mg. It was confirmed that the remaining amount of the contents due to adhesion in the blending tank and the soft capsule manufacturing apparatus was very small, and there was no problem industrially.

(比較例1)
ウコンオレオレジン(丸善製薬株式会社製)50重量%、MCT(理研ビタミン株式会社製,商品名:アクターM2)25重量%、テトラグリセリンモノオレイン酸エステル(阪本薬品工業株式会社製,商品名:SYグリスターMO−3S,HLB値=8.8)25重量%を用い、40℃℃加温条件下でパドルミキサーにより混合した。得られたウコン抽出物含有組成物は乳化剤が分離し不均一な状態であり、流動性や付着性は評価できなかった(表1)。
(Comparative Example 1)
Turmeric oleoresin (manufactured by Maruzen Pharmaceutical Co., Ltd.) 50% by weight, MCT (manufactured by Riken Vitamin Co., Ltd., trade name: Actor M2) 25% by weight, tetraglycerin monooleate (manufactured by Sakamoto Pharmaceutical Co., Ltd., trade name: SY (Glister MO-3S, HLB value = 8.8) 25% by weight was mixed with a paddle mixer under heating at 40 ° C. The obtained turmeric extract-containing composition was in a non-uniform state because the emulsifier was separated, and the fluidity and adhesion could not be evaluated (Table 1).

(比較例2)
ウコンオレオレジン(丸善製薬株式会社製)40重量%、ゴマ油(カドヤ製油株式会社製)55重量%、モノグリセリンモノステアリン酸エステル(理研ビタミン株式会社製,商品名:エマルジーMS,HLB値=4.3)5重量%を用い、40℃加温条件下でパドルミキサーにより混合した。得られたウコン抽出物含有組成物は、流動性は改善されていたが付着性や均一性はあまり改善されておらず、粘結性の改善は必ずしも十分とは言い難いものであった(表1)。また、実施例9と同様方法でソフトカプセルを作成したところ、調合タンク内およびソフトカプセル製造装置内へ相当量の付着が確認され、工業的には問題のあることが確認された。
(Comparative Example 2)
Turmeric oleoresin (manufactured by Maruzen Pharmaceutical Co., Ltd.) 40% by weight, sesame oil (manufactured by Kadoya Oil Co., Ltd.) 55% by weight, monoglycerin monostearate (manufactured by Riken Vitamin Co., Ltd., trade name: Emulsy MS, HLB value = 4. 3) Using 5% by weight, the mixture was mixed by a paddle mixer under heating at 40 ° C. The obtained turmeric extract-containing composition had improved fluidity but not much improved adhesion and uniformity, and the caking improvement was not necessarily sufficient (Table 1). Further, when soft capsules were prepared in the same manner as in Example 9, a considerable amount of adhesion was confirmed in the preparation tank and the soft capsule manufacturing apparatus, and it was confirmed that there was an industrial problem.

(比較例3)
ウコンオレオレジン(丸善製薬株式会社製)45重量%、菜種油(鐘淵化学工業株式会社製)55重量%を用い、40℃加温条件下でパドルミキサーにより混合した。得られたウコン抽出物含有組成物は、流動性、付着性、均一性何れもあまり改善されておらず、粘結性の改善は必ずしも十分とは言い難いものであった(表1)。
(Comparative Example 3)
Turmeric oleoresin (manufactured by Maruzen Pharmaceutical Co., Ltd.) 45% by weight and rapeseed oil (manufactured by Kaneka Chemical Co., Ltd.) 55% by weight were mixed with a paddle mixer under 40 ° C. heating conditions. The obtained turmeric extract-containing composition was not improved so much in fluidity, adhesion, and uniformity, and the caking improvement was not necessarily sufficient (Table 1).

(比較例4)
ウコンオレオレジン(丸善製薬株式会社製)100重量%、すなわち単独では流動性、付着性共にかなり悪かった。
(Comparative Example 4)
Turmeric oleoresin (manufactured by Maruzen Pharmaceutical Co., Ltd.) 100% by weight, that is, the fluidity and adhesion were considerably poor by themselves.

Figure 2005097152
Figure 2005097152

ウコン抽出物を高濃度に含有するにもかかわらず、粘度が高くなく、且つ容器などへの付着性が低い組成物を提供できる。従って、例えばウコンの有用成分を高濃度でソフトカプセル等へ封入することも容易になる。 In spite of containing the turmeric extract at a high concentration, it is possible to provide a composition having a low viscosity and low adhesion to a container or the like. Therefore, for example, it becomes easy to enclose a useful component of turmeric in a soft capsule or the like at a high concentration.

Claims (8)

ウコン抽出物を40重量%を超えて含有し、且つ、中鎖脂肪酸トリグリセリド及び/又は油脂及び/又はHLB値が8.5以下の親油性乳化剤からなることを特徴とするウコン抽出物含有組成物。 A turmeric extract-containing composition comprising more than 40% by weight of a turmeric extract and comprising a medium-chain fatty acid triglyceride and / or fat and oil and / or a lipophilic emulsifier having an HLB value of 8.5 or less . 中鎖脂肪酸トリグリセリド及び/又はHLB値が8.5以下の親油性乳化剤からなることを特徴とする請求項1記載のウコン抽出物含有組成物。 The turmeric extract-containing composition according to claim 1, comprising a medium-chain fatty acid triglyceride and / or a lipophilic emulsifier having an HLB value of 8.5 or less. 親油性乳化剤がグリセリン脂肪酸エステルであることを特徴とする請求項1又は2に記載のウコン抽出物含有組成物。 The turmeric extract-containing composition according to claim 1 or 2, wherein the lipophilic emulsifier is a glycerin fatty acid ester. 親油性乳化剤がポリグリセリン脂肪酸エステルであることを特徴とする請求項1又は2に記載のウコン抽出物含有組成物。 The turmeric extract-containing composition according to claim 1 or 2, wherein the lipophilic emulsifier is a polyglycerol fatty acid ester. ポリグリセリン脂肪酸エステルの構成脂肪酸が不飽和であることを特徴とする請求項4記載のウコン抽出物含有組成物。 The turmeric extract-containing composition according to claim 4, wherein the constituent fatty acid of the polyglycerol fatty acid ester is unsaturated. 親油性乳化剤がジグリセリンモノオレイン酸エステルであることを特徴とする請求項1又は2に記載のウコン抽出物含有組成物。 The turmeric extract-containing composition according to claim 1 or 2, wherein the lipophilic emulsifier is diglycerin monooleate. マルチプル・リスク・ファクター症候群を予防又は改善する効果を有することを特徴とする請求項1〜6の何れかに記載のウコン抽出物含有組成物。 The turmeric extract-containing composition according to claim 1, which has an effect of preventing or improving multiple risk factor syndrome. 請求項1〜7の何れかに記載の組成物を封入してなるカプセル。 A capsule formed by encapsulating the composition according to claim 1.
JP2006511991A 2004-03-31 2005-03-23 Turmeric extract-containing composition with improved caking properties Withdrawn JPWO2005097152A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004107212 2004-03-31
JP2004107212 2004-03-31
PCT/JP2005/005175 WO2005097152A1 (en) 2004-03-31 2005-03-23 Turmeric extract-containing composition having improved caking capacity

Publications (1)

Publication Number Publication Date
JPWO2005097152A1 true JPWO2005097152A1 (en) 2008-02-28

Family

ID=35124833

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006511991A Withdrawn JPWO2005097152A1 (en) 2004-03-31 2005-03-23 Turmeric extract-containing composition with improved caking properties

Country Status (2)

Country Link
JP (1) JPWO2005097152A1 (en)
WO (1) WO2005097152A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014185107A (en) * 2013-03-22 2014-10-02 Kobayashi Pharmaceutical Co Ltd Oral composition

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5334492B2 (en) * 2008-08-13 2013-11-06 富士化学工業株式会社 High concentration astaxanthin extract
PE20121202A1 (en) * 2009-03-26 2012-10-01 Abbott Lab NUTRITIONAL COMPOSITION INCLUDING CURCUMINOIDS AND METHODS TO MAKE IT
JP2013202005A (en) * 2012-03-29 2013-10-07 National Agriculture & Food Research Organization Curcumin-containing oil and fat, and method for producing the same
US20140056828A1 (en) * 2012-08-21 2014-02-27 Indiran Pather Novel formulations and uses for curcuma extracts
CN105056157A (en) * 2015-09-22 2015-11-18 郭新奎 Composition for treating acute pancreatitis and preparation method thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0965864A (en) * 1995-08-30 1997-03-11 Riken Vitamin Co Ltd Antioxidant preparation for food
JPH09143086A (en) * 1995-11-22 1997-06-03 San Eng:Kk Drug and cosmetic for treatment of skin disease
JPH10179086A (en) * 1996-11-05 1998-07-07 Riken Vitamin Co Ltd Oil-solubilizing liquid containing plant sterol as well as drinks and their production
JP2001161306A (en) * 1999-12-03 2001-06-19 Ezaki Glico Co Ltd Method for producing gelatin capsule excellent in palatability
TWI329516B (en) * 2000-12-12 2010-09-01 Kaneka Corp Composition for preventing or ameliorating multiple risk factor syndromes and visceral fat-type obesity
JP2003137799A (en) * 2001-03-28 2003-05-14 Kiyotoshi Oshiro Diacylglycerol solution including turmeric and method for producing the same
DE60328002D1 (en) * 2002-04-04 2009-07-30 Kaneka Corp PROCESS FOR PREPARING A FAT COMPOSITION WITH HYDROPHOBIC COMPONENTS OF GLYCYRRHIZA

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014185107A (en) * 2013-03-22 2014-10-02 Kobayashi Pharmaceutical Co Ltd Oral composition

Also Published As

Publication number Publication date
WO2005097152A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
JP4685355B2 (en) Process for producing oil and fat composition containing licorice hydrophobic component
JPWO2005097152A1 (en) Turmeric extract-containing composition with improved caking properties
JP5820256B2 (en) Self-emulsifying formulation
JP7017043B2 (en) Powdered fats and oils, foods and drinks containing them
JP2007512407A (en) Oil composition rich in diglyceride of conjugated linoleic acid
JP2011012003A (en) Emulsion composition for soft capsule and soft capsule
KR20170083048A (en) Powdered oil/fat, food/beverage including powdered oil/fat, and method for producing powdered oil/fat
JP5033553B2 (en) Emulsification stabilizer
JP6689042B2 (en) Acid oil-in-water emulsion food
JP2010235563A (en) Emulsion composition for soft capsule and soft capsule agent
JP2017143753A (en) O/d type emulsion composition, oil-in-water type emulsion composition, food or drink, and ingredient for food
WO2013147131A1 (en) Antioxidant composition
WO2006134970A1 (en) Coenzyme q10-containing water-soluble composition and process for production thereof
JP7044457B2 (en) Unraveling agent for noodles and noodles
KR20110044968A (en) Plant Extracts and PFAFA Combinations
JPH0542411B2 (en)
JP6843376B2 (en) Capsule coating composition and capsule
WO2012105551A1 (en) Water-soluble preparation containing physiologically active substance and process for production thereof
JP6101854B1 (en) Propolis extract-containing composition for capsule and capsule
JP6682375B2 (en) Acid oil-in-water emulsion food
EP3000328B1 (en) Fat composition
JP6325890B2 (en) Oil composition
WO2012014903A1 (en) Fat-containing composition and oral formulation containing same
WO2007046333A1 (en) Emulsifying agent and emulsion composition prepared with the same
JP6325866B2 (en) Oil composition

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080122

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20081127